Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Comparing the Efficacy and Safety of Epirubicin Combined With Cyclophosphamide Followed by Docetaxel (EC-T) Verses Paclitaxel Combined With Carboplatin (PCb) in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

NCT04193059 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04193059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04193059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Comparing the Efficacy and Safety of Epirubicin Combined With Cyclophosphamide Followed by Docetaxel (EC-T) Verses Paclitaxel Combined With Carboplatin (PCb) in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 20, 2019
Completion date
July 31, 2027
Enrollment
1,560 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer